Botanix BTX 1503 Clinical Trial Update
· BTX 1503 acne Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019
· Positive patient testimony from one of the first patients enrolled in the BTX 1503 acne Phase 2 clinical trial
Philadelphia PA and Sydney Australia, 12 September 2018 -- Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”), is pleased to advise that following the recent commencement of the BTX 1503 acne Phase 2 clinical trial, one of the first patients enrolled into the clinical trial has demonstrated promising early results and provided a positive testimony.
Have you seen our earlier videos?
P: +1 215 767 4184
P: +61 3 8582 4800
The Capital Network
P: +61 419 815 386